Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Alzheimer's disease (AD), the commonest cause of dementia, is estimated to affect over 400 000 people in the UK,1 with numbers around the world set to rise dramatically as the population ages. Distinguishing AD from other causes of cognitive impairment is important for numerous reasons, including provision of appropriate care and access to medications. As and when disease-modifying therapies become available, the priority for earlier and more accurate diagnosis will increase still further.
An important starting point is the definition of AD. This is not as straightforward as it might seem: concepts of AD have evolved rapidly over recent years, with new criteria proposed as recently as 2011 continuing to provoke debate. Ultimately, a diagnosis of AD requires pathological confirmation. However, even a pathological diagnosis comes with a degree of uncertainty2 and the pathological phenotype of AD is itself heterogeneous.3
Diagnosis in life has until relatively recently depended on very broad clinical criteria dating back to the 1980s, mandating that an individual be ‘demented’, that is, have progressive impairment of memory and at least one other cognitive domain sufficient to impact on activities of daily living.4 The new criteria for diagnosis of AD have built on a large body of work demonstrating that biomarkers of AD—including MRI, cerebrospinal fluid (CSF) and positron emission tomography (PET)—may improve diagnostic sensitivity and specificity. The criteria also reflect a growing move to try to achieve earlier diagnosis. The new criteria propose that AD can be diagnosed with different degrees of certainty based on the extent of the cognitive deficits and presence/absence of biomarker abnormalities. These criteria were reviewed recently in this journal.5
For the purposes of this article and with the aim of providing a practical guide to the differential diagnosis of AD, we will first consider the ‘typical’ clinical …
Contributors Both authors contributed to the writing of this paper.
Funding This work was supported by the National Institute for Health Research (NIHR) Biomedical Research unit in Dementia based at University College London Hospitals (UCLH) and University College London (UCL). The views expressed by the authors are not necessarily those of the NHS, NIHR or the Department of Health. Dr Schott is a HEFCE Clinical Senior Lecturer and receives funding from Alzheimer's Research UK and the Alzheimer's Society. Dr Warren is in receipt of a Wellcome Trust Senior Clinical Fellowship (Grant No. 091673/Z/10/Z).
Competing interest None.
Provenance and peer review Commissioned, externally reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Biomarkers in dementia: clinical utility and new directions
- Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease
- An algorithmic approach to structural imaging in dementia
- Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage
- Presenile dementia syndromes: an update on taxonomy and diagnosis
- Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias
- Brain imaging in dementia
- Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease
- Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis